FindTrial
Sign In

RESULTS OF TWO MODES (GAMMA KNIFE AND RUTHENIUM PLAQUE BRACHYTHERAPY) FOR TREATMENT OF UVEAL MELANOMA (A TYPE OF EYE CANCER)

CLINICAL OUTCOMES OF GAMMA KNIFE AND RUTHENIUM PLAQUE BRACHYTHERAPY IN THE TREATMENT OF UVEAL MELANOMA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044845
Enrollment
20
Registered
2022-08-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C693- Malignant neoplasm of choroid

Interventions

Intervention1: GAMMA KNIFE: Patients of uveal melanoma will be subjected to gamma knife.A high resolution MRI will be done to provide orientation and localization of target.Treatment planning is done

Sponsors

Dr Rajendra Prasad Centre for Ophthalmic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A) CHOROIDAL MELANOMA 1. GAMMA KNIFE 1. Small,medium and large choroidal melanoma according to COMS Classification. 2. Patients giving consent for the study 2. RUTHENIUM PLAQUE BRACHYTHERAPY 1. Small to medium(thickness melanoma according to COMS Classification. 2. Patients giving consent for the study B) IRIS/CILIARY MELANOMA 1. GAMMA KNIFE 1. Involvement of 1-6 clock hours of iris 2. Largest basal dimension of tumor >3 mm 3. Patients giving consent for the study 2) RUTHENIUM PLAQUE BRACHYTHERAPY 1. Involvement of 1-6 clock hours of iris 2. Largest basal dimension of tumor >3 mm 3. Patients giving consent for the study

Exclusion criteria

Exclusion criteria: A) CHOROIDAL MELANOMA 1. GAMMA KNIFE 1. Tumors with gross extraocular extension 2. Patients with painful blind eye 3. Presenting with metastatic choroidal melanoma 2. RUTHENIUM PLAQUE BRACHYTHERAPY 1. Tumors with gross extraocular extension 2. Patients with painful blind eye 3. Presenting with metastatic choroidal melanoma B) IRIS/ CILIARY BODY MELANOMA 1. GAMMA KNIFE 1. Seeding in anterior chamber 2. Melanomas with secondary glaucoma 3. Scleral/extraocular extension 4. Tapioca/ Ring Melanoma 2. RUTHENIUM PLAQUE BRACHYTHERAPY 1. Seeding in anterior chamber 2. Melanomas with secondary glaucoma 3. Scleral/extraocular extension 4. Tapioca/ Ring Melanoma

Design outcomes

Primary

MeasureTime frame
1. Globe salvage rate-percentage of cases where enucleation was not required 2. Local tumor control- %decrease in tumor diameter and height on USG. 3. Vision salvage rate-assessing post procedure visual outcomes 4. Local recurrence of tumor 5. Need for enucleation 6. Occurence of Extraocular extension 7. Occurence of Distant metastasisTimepoint: 6 months—

Secondary

MeasureTime frame
Development of local complications subsequent to therapy: 1. Radiation Retinopathy 2. Radiation optic neuropathy 3. Glaucoma 4. Radiation Maculopathy 5. Cataract 6. Corneal ErosionsTimepoint: 1 month, 2 month,3 month,4 month,5 month,6 month—

Countries

India

Contacts

Public ContactDr Aruja Gangwani

All India Institute of Medical Sciences, New Delhi

bhavna2424@hotmail.com9654842424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026